Alan: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.alanmeds.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Alan” on the pictured label, suggesting Alan is the compounder of those drugs when in fact it is not.”

2. 2

   “In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2).”

3. 3

   “The representations identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

alanmeds.com returned a live storefront when we checked in August 2026, advertising compounded semaglutide plans with published monthly prices, multi-month terms and a promotional offer, alongside a broader wellness catalogue.

There is nothing to fact-check in this letter, and that is what makes it worth having. FDA looked at the site in December 2025 and wrote down one thing: the vial in the photograph carries the seller's name, and a name on a drug label means the named company made it. No efficacy claim was quoted, no brand comparison, no price copy — unlike five other letters signed the same day. Anyone who treats the existence of a warning letter as a verdict on a company will get this one badly wrong. What it actually tells a price shopper is narrower and more practical: the branding on the box is the storefront's, the compounder is someone FDA says is not named there, and two subscriptions that look different on the label may not be different in what arrives.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Alan failed to respond.